{"Title": "The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis", "Year": 2018, "Source": "Neurology", "Volume": "90", "Issue": 15, "Art.No": null, "PageStart": 677, "PageEnd": 678, "CitedBy": 7, "DOI": "10.1212/WNL.0000000000005279", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052225603&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85052225603", "SubjectAreas": [["Neurology (clinical)", "MEDI", "2728"]], "AuthorData": {"25958454400": {"Name": "Schoonheim M.M.", "AuthorID": "25958454400", "AffiliationID": "60008734, 60001997", "AffiliationName": "Department of Anatomy and Neurosciences, Amsterdam Neuroscience, VU University Medical Center"}, "7003671038": {"Name": "Ciccarelli O.", "AuthorID": "7003671038", "AffiliationID": "60024544, 60172638", "AffiliationName": "National Institute for Health Research, University College London Hospitals Biomedical Research Centre"}}}